These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 338625)

  • 1. Effect of temperature on survival of Bacteroides fragilis subsp. fragilis and Escherichia coli in pus.
    Hagen JC; Wood WS; Hashimoto T
    J Clin Microbiol; 1977 Dec; 6(6):567-70. PubMed ID: 338625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chilling on the survival of Bacteroides fragilis.
    Hagen JC; Wood WS; Hashimoto T
    J Clin Microbiol; 1976 Nov; 4(5):432-6. PubMed ID: 993326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quantitative and histological demonstration of pathogenic synergy between Escherichia coli and Bacteroides fragilis in guinea-pig wounds.
    Kelly MJ
    J Med Microbiol; 1978 Nov; 11(4):513-23. PubMed ID: 364068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro stimulation of Bacteroides fragilis growth by Escherichia coli.
    Hagen JC; Wood WS; Hashimoto T
    Eur J Clin Microbiol; 1982 Dec; 1(6):338-43. PubMed ID: 6761111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of short-chain fatty acids on in vitro bacterial growth of Bacteroides fragilis and Escherichia coli.
    Mortensen FV; Møller JK; Hessov I
    APMIS; 1999 Feb; 107(2):240-4. PubMed ID: 10225323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escherichia coli hemoglobin protease autotransporter contributes to synergistic abscess formation and heme-dependent growth of Bacteroides fragilis.
    Otto BR; van Dooren SJ; Dozois CM; Luirink J; Oudega B
    Infect Immun; 2002 Jan; 70(1):5-10. PubMed ID: 11748157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
    Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early events after intra-abdominal infection with Bacteroides fragilis and Escherichia coli.
    Verweij WR; Namavar F; Schouten WF; MacLaren DM
    J Med Microbiol; 1991 Jul; 35(1):18-22. PubMed ID: 2072375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
    Brook I
    Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection caused by Escherichia coli and Bacteroides fragilis within fibrin clots.
    Dunn DL; Rotstein OD; Simmons RL
    Arch Surg; 1984 Feb; 119(2):139-44. PubMed ID: 6365029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
    Rotstein OD; Kao J
    Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translocation and survival of Bacteroides fragilis after thermal injury.
    Gianotti L; Alexander JW; Pyles T; Gennari R; Babcock GF
    J Burn Care Rehabil; 1995; 16(2 Pt 1):127-31. PubMed ID: 7775505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic synergy between Escherichia coli and Bacteroides fragilis: studies in an experimental mouse model.
    Verweij-van Vught AM; Namavar F; Sparrius M; Vel WA; MacLaren DM
    J Med Microbiol; 1985 Jun; 19(3):325-31. PubMed ID: 3892009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wound infection: a controlled clinical and experimental demonstration of synergy between aerobic (Escherichia coli) and anaerobic (Bacteroides fragilis) bacteria.
    Kelly MJ
    Ann R Coll Surg Engl; 1980 Jan; 62(1):52-9. PubMed ID: 6987938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The growth and survival of capsulate and non-capsulate Bacteroides fragilis in vivo and in vitro.
    Patrick S; Reid JH; Larkin MJ
    J Med Microbiol; 1984 Jun; 17(3):237-46. PubMed ID: 6726783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamics of intraperitoneal growth and elimination of Escherichia coli and Bacteroides fragilis in porcine faecal peritonitis treated with fosfomycin.
    Berglund J; Andåker L; Skau T; Nyström PO
    J Antimicrob Chemother; 1991 Apr; 27(4):527-33. PubMed ID: 1856131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic lethality in experimental infections with Escherichia coli and Bacteroides fragilis.
    Rodloff AC; Hahn H
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Oct; 258(1):112-9. PubMed ID: 6395577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model.
    Rotstein OD; Kao J; Houston K
    J Med Microbiol; 1989 Aug; 29(4):269-76. PubMed ID: 2668529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.